Olive Leaf Report Documents Promising Therapeutic Interventions for 9-11 Workers
Treatment for High Levels of Mercury and Lead Toxicity In Ground Zero Rescue and Recovery Workers and Lower Manhattan Residents
Philadelphia, October 24, 2006 — In a Special Report published in the September/October issue of EXPLORE: The Journal of Science and Healing, Claire Haaga Altman, President and Dr. Kamau Kokayi, MD, Medical Director of the Olive Leaf Wholeness Center in New York City outlined the program used to treat 160 uniformed service personnel and residents of Lower Manhattan who were exposed to the air at Ground Zero during the 9-11 attacks.
More than 2400 chemicals and metals were combusted when the twin towers collapsed. The major ones identified as being potentially toxic to humans were: asbestos, lead, mercury, dioxins and furans, diesel fuels and oils, benzenes and other volatile organic compounds. Project Olive ReLeaf found most individuals who were exposed had 8 or more serious health complaints including: severe respiratory problems, digestive problems, skin rashes, sleeplessness, anxiety, depression, weight gains and elevated blood pressure, lethargy, and recurrent headaches.
This is consistent with the findings of the recent Mt Sinai Study, which unveiled that roughly 70 percent of nearly 10,000 workers who were tested from 2002 to 2004 had new or substantially worsened respiratory problems while or after working at ground. (This study was recently published in Environmental Health Perspectives, the journal of the National Institute of Environmental Health Sciences.) In addition, a recent study by the New York City Fire Department found that on average firefighters who worked at Ground Zero have lost up to 12 years of lung capacity as a result of their exposure to the toxins at the site.
The Olive ReLeaf team had suspected since 2002 that heavy metal toxicity might be a causal factor for many of the symptoms the rescue workers and Lower Manhattan residents were reporting. A challenge urine test was administered to measure heavy metal toxicity. Eighty-five percent (85%) of those tested had excessively high levels of lead and mercury in their systems.
A key component of the treatment in the Olive Releaf program were given Chelation therapy using DMSA (Dimercaptuosuccinic acid), an FDA approved sulfur compound. In addition, adjunctive therapies to assist with the detoxification process and build the immune system were offered including, acupuncture, bioenergetic neuromodulation, Chinese herbal medicine, antioxidants, intravenous glutathione, and supplementation with NAC, glutathione, alpha lipoic acid and Vitamin C.
After 3-4 months of treatment, the first cohort of 100 reported significant (greater than 60%) improvement in all symptoms.
# # #
EXPLORE: The Journal of Science and Healing addresses the scientific principles behind, and applications of, evidence-based healing practices from a wide variety of sources, including conventional, alternative, and cross-cultural medicine. It is an interdisciplinary journal that explores the healing arts, consciousness, spirituality, eco-environmental issues, and basic science as all these fields relate to health.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
Tel: +1 215 239 3654